Dyadic International, Inc. · NASDAQ:DYAI
Dyadic International — Corporate Update (December 2021)
21 slides from Dyadic International's corporate update, Dec 2, 2021
Slide 1: C1 Technology Platform against SARS-CoV-2 Variants of Concern
November 29, 2021 DYADIC : echnology Platform igainst SARS-CoV-2 Variants of Concern with a rapid ent pandemic and future biological threats utilizing the 9n technology of tomorrow to combat the threats of today
Slide 2: Safe Harbor Regarding Forward-looking Statements
Safe Harbor Regarding Forward-looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, i
Slide 3: Our Mission, Transforming Biomanufacturing
Our Mission, Transforming Biomanufacturing “Improving how we feed", fuel’, and heal the world by utilizing modern biotechnology to revolutionize science, medicine, agriculture’.” “Providing a cost-effective solution that increases outputs and to meet the growing demand for protein production.” “Ulti
Slide 4: C1-cells are an exceptional strain of genetically engineered fungus
“C1-cells” are an exceptional strain of genetically engineered fungus Broad application of C1 has expanded through 20 years of commercial engineering 1892 2005 2016 Today l C™R™NNRN™N™T—TTTT TF > C1 wildtype strain produces Enzyme library developed Acceleration of Proof-of-Concept C1 Platform commer
Slide 5: C1-Cell Technology: Proven, Rapid, Efficient Antigen Manufacturing
C1-Cell Technology: Proven, Rapid, Efficient Antigen Manufacturing Robust, versatile and scalable platform for production of Covid-19 variant of concern and others + Status of C1-based DYAI-100 COVID-19 vaccine development ACE2 - ELISA Assay + Stable C1-cell expressed RBD-CTag antigen Stable C1-cell
Slide 6: SARS-CoV-2 RBD Variants have key advantages as a vaccine antigen
SARS-CoV-2 RBD Variants have key advantages as a vaccine antigen Receptor binding domain (RBD) Minimization advantage of spike protein antigen to the RBD: Antigen minimization + Exposure of key neutralizing epitopes on the RBD to the immune system that are hidden in the closed spike conformation —_
Slide 7: C1 Protein Production Platform
C1 Protein Production Platform Site Directed Transformation Method yields Rapid generation of Stable RBD Variant Cell Lines The same rapid — will be used to construct a new cell line with the new gene C1 genome 5 C1 genome \ J \ J Wuhan RBD variant integrated to C1 genome — NewRBD variant (Omicron)
Slide 8: C1 Fermentation Technology — Microbial
C1 Fermentation Technology — Microbial Fed-Batch Process Well Defined easy Technology Transfer at flexible scaling Fed-batch Process + Fully defined low-cost medium gem aims s2ot68 nes + Fed-batch technology with glucose feeding NH,OH for + Wide range of conditions pH: 5-8, Temp: 20 - 45°C Seed flas
Slide 9: Comparison of Fab production in SSB or SUB under different conditions
Comparison of Fab production in SSB or SUB under different condi Certolizumab production with C1 in Single use Bioreactor (SUB) GE’s Xcellerex™ XDR-50 MO =e SSA to || -eesua Fab (g/L) Fab production kinetics in either SSB or SUB under two different 2 operating conditions + Six batches were tested in
Slide 10: SARS-CoV-2 Spike RBD Is A Key Target For Potent Neutralizing mAbs
SARS-CoV-2 Spike RBD Is A Key Target For Potent Neutralizing mAbs Advancing Towards Phase | clinical study 1H 20221 + In~2months, we developed a C1 cell line expressing the Receptor Binding Domain (23kDa) of SARS- CoV-2 spike protein C1 stable cell line was developed that expressed the RBD ori trans
Slide 11: Potential Commercial Scale Production of C1-RBD With/Without MPSP
Potential Commercial Scale Production of C1-RBD With/Without MPSP “* C1-RBD fermentation capacities for different dose requirements based on 5 days fermentation at various scales 4 600 6 000 60 000 300 3000 30000 2.0 2.0 2.0 2.0 2.0 2.0 60 80 60 60 60 60 60 80 80 80 80 80 “ C1-expressed SARS-CoV-2 R
Slide 12: Phase 1 with C1-cell SARS-CoV-2 RBD Recombinant Vaccine in 2021
Phase | with C1-cell SARS-CoV-2 RBD Recombinant Vaccine in 2021 Prove Safety and Efficacy of DYAI-100 Vaccine Candidate in Humans 2RBD protein based rVaccine | pyapic' Developed the C1 -SARS.CoV- VY (DYAI-100 Vaccine Candidate) VY Coordination of clinical trials for anistal vaccines CRO > Completed
Slide 13: Pre-Clinical Study (1)
Pre-Clinical Study (1) Mice study demonstrated that the C1-RBD-CTag induced neutralizing antibodies at high level as Oo Pp PS Day after first vaccination DirectRBD ELISA Serum samples obtained at 19, 28, 43 and 50 dpv were tested in a direct ELISA assay. For each mouse (n = 10) serum dilutions scori
Slide 14: Pre-Clinical Study (2)
Pre-Clinical Study (2) Challenge Mice study demonstrated that the C1-S-RBD induced full protection A. Vaccination of K18-hACE2 transgenic mice: B. 2 groups of transgenic mice were vaccinated with 20 ug of RBD-C formulated with Alhydrogel. Group | of 8 mice were vaccinated: Prime = Day 1 and Boost at
Slide 15: Production of ALPHA-RBD-C-tag variant
Production of ALPHA-RBD-C-tag variant Expression in 1L Fermenter Fermentation and Small-scale purification Larger scale purification ACE2 ELISA Assay aT] 7 on oe cae oe lel ee 5 a : e-aen & WWeG@SSESLRERL LE KE q wl 3 » =e a : ly “0 i “3 zc a Q = a =¢ a UK RED 10g lt om --. -—@oo~ eal 2 40 6a] Ce fe
Slide 16: Production of Covid-19 BETA-RBD-C-tag variant
Production of Covid-19 BETA-RBD-C-tag variant Expression in 1L Fermenter Fermentation and Small-scale purification Larger scale purification ACE2 ELISA Assay S656 6 Sabu 2... Br222588S3 88 — ss - G7 G3 Pooled G1-G9 Final dialyzed ~-<eBee--<2 DYADIC. MT521 ~ MT522 Mm@icce clece SEEREESEE wo OFX SSR S
Slide 17: Production of Covid-19 Gamma-RBD-C-tag variant
Production of Covid-19 Gamma-RBD-C-tag variant Expression in 1L Fermenter [RERMENLEEN ET) larger scale purification ACE2 ELISA Assay Small-scale purification a 3 » gy os mis o @& = 3 EEE age é zg g o * o ges Ssosssssesié ° 7 _—= ) £15 i 5 a) ‘4 Ba 1 > o¢ 3, ma-sreretee o-3 al ia 5A 82 5) “8 20 400 6
Slide 18: Production of Covid-19 Delta-RBD-C-tag variant
Production of Covid-19 Delta-RBD-C-tag variant Expression in 1L Fermenter Pouce Ene) Larger scale purification ACE2 ELISA Assay Small-scale purification Fermentation RBD-Delta-Ctag, BTG Elisa MT540 2 D3 D4 DS -20 - srw w mas me wae mawanaze FE 150 - = & Fes 10 The Tenner pad 100 ee peltectes bt -—-5
Slide 19: Production of Alpha, Beta, Gamma - SARS-CoV-2 C-Tag Variant RBD's
Production of Alpha, Beta, Gamma - SARS-CoV-2 C-Tag Variant RBD’s Co-Expression of 3x Covid-19 RBD’s variants in One C1 Strain Intact LC-MS ACE2 ELISA Assay 5 days Fermentation foe pga 205 45 26 36 4d Sd 1 { fiee eo8s 56 bE eo roa Le tut t t ( C-tag and Repligen purification: In 121 hr. — 1.34 g/L-1
Slide 20: Optimization of C1-SARS-Cov-2 RBD Fermentation is in Process
Optimization of C1-SARS-Cov-2 RBD Fermentation is in Process Further Fermentation Optimization based on Media, Inoculumand Feeding Regimen Base process Richer inoculum Further improved Increased YE media inoculum media concentration in production media > Fermentation was done with the single gene co
Slide 21: Global Health Access, Affordability & Equity
GLOBAL HEALTH ACCESS, AFFORDABILITY & EQUITY C1 Technology has the Power to Transform Global Health North America South America Africa (including Middle East) Australia 2
Dyadic International — Corporate Update (December 2021) on 6ix